至少，制药企业仍然盈利。
Pharmaceuticals companies, at least, are still making profits.
但除了调整销售方式，制药企业还有很多事要做。
But drugs companies will have to do more than tweak their sales methods.
几乎所有主流制药企业都关注于肿瘤药物的研发。
Almost all major pharmaceutical companies are now focused on oncology drug development.
工艺验证是制药企业实施GMP规范的关键问题。
Process validation is a key in execution of GMP in pharmaceutical enterprise.
工艺验证一直是生物制药企业争论和困惑的话题。
Process validation continues to be a topic of much debate and confusion for biopharmaceutical manufacturers.
药品很便宜，他们不须依赖西方的制药企业联合体。
The drugs are cheap and they don't depend on [Western pharmaceutical] cartels.
这样的策略会使CPG公司越来越象大型制药企业。
Such strategies may eventually make CPG firms even more like big pharmaceutical companies.
与此同时，许多公司已经开始向制药企业提供这类技术的服务。
Meanwhile, a number of firms have already been established to offer the technique to drugmakers.
目前，我国的制药企业正面临着结构性调整的压力。
Presently, the pharmaceutical industry of our country is facing the pressure of structural adjustment.
之所以这样说是因为制药企业有大量而可靠的现金来源。
One reason to think so is that the pharmaceutical industry is known for its large, reliable cashflows.
大型制药企业的圈地是否预示着两大产业期待已久的趋同？
So will Big Pharma’s land-grab succeed, heralding the long-awaited convergence of the two industries?
华北制药集团有限责任公司是当前中国最大的化学制药企业之一。
North China pharmaceutical Group Corporation (NCPC) is one of the largest pharmaceutical manufacturers in China.
例如，Icon为制药企业提供临床试验外包服务，Knoll制造办公家具。
For instance, Icon provides outsourced clinical-trial services to pharmaceutical companies, and Knoll makes office furniture.
桑特拉说，当他后来在一家全球性制药企业求职时，他的回答让面试官很有共鸣。
When the manager pursued an opportunity at a global drug maker, his revamped response “really resonated with the interviewer, ” says Mr. Santora.
桑特拉说，当他后来在一家全球性制药企业求职时，他的回答让面试官很有共鸣。
When the manager pursued an opportunity at a global drug maker, his revamped response 'really resonated with the interviewer,' says Mr. Santora.
桑特拉说，当他后来在一家全球性制药企业求职时，他的回答让面试官很有共鸣。
When the manager pursued an opportunity at a global drug maker, his revamped response "really resonated with the interviewer," says Mr. Santora.
人本药业是集生物毒素生产、研究、药物开发于一体的生物制药企业。
The medicine man is a biological toxin production, research and drug development in one of the bio-pharmaceutical companies.
曾经是投资者最爱的那些富有的制药企业，正在急切地寻找着治疗自身各种疾病的办法。
Drugs firms, once rich and the favourites of investors, are urgently seeking cures to a variety of ailments.
制药企业高额贿赂美国儿童精神病学家以宣传他们的药物治疗，英国也出现了这种情况。
Drug companies are bribing American child psychiatrists with huge research grants to advocate this kind of treatment, and it's beginning to happen in the UK.
而制药企业对不利结果的掩盖显然是公然背叛了这些试验参与者的信任和付出。
Burying unwelcome results is an unambiguous betrayal of their trust and generosity.
阿斯利康公司总裁布伦南曾经做过药品推销员，他也承认制药企业可能在这方面做过头了。
AstraZeneca's boss, Mr Brennan, is a former drugs salesman and he acknowledges that companies may have gone too far.
制药企业正努力让他们在研发上的投入更加物有所值，所以你可以期待这种趋势会持续下去。
With drug companies trying to get more bang for their research and development buck, look for the trend to continue.
制药企业不仅要改变生产药品的方式，而且要改变销售药品的方式—特别是在美国。
Firms are not only changing how they make drugs, but how they market them-especially in America.
例如美国国立卫生研究院的拨款产生了原始的创意，制药企业再将这些创意变成有利可图的药品。
The grants doled out by America’s National Institutes of Health, for example, generate the raw ideas that pharmaceutical firms turn into profitable medicines.
OEM是在国际市场十分流行并行之有效的生产方式，但在生物制药企业中还不多见。
OEM was a popular and effective production mode in the international market, but it was still rare in the biological pharmacy enterprises.
数周来，关于全球最大的制药企业辉瑞公司，将会采取星爆式重组的方式进行拆分的猜测不绝于耳。
FOR weeks, speculation has been rife that Pfizer, the world's biggest pharmaceuticals company, will break itself into pieces, a restructuring move known as the starburst.
对大多数大型制药企业而言，下定决心走多元化经营的道路实在是一种应对目前困境的正确的选择。
That is especially true if you are desperate to diversify, as most big pharmaceutical companies are these days.
如果企业（例如制药企业）一味追逐利润，怎么能指望它们针对缺乏购买力的穷人的疾患投入研发资金呢？
If businesses, like the pharmaceutical industry, are driven by the need to make a profit, how can we expect them to invest in R&D for diseases of the poor, who have no purchasing power?
如果企业（例如制药企业）一味追逐利润，怎么能指望它们针对缺乏购买力的穷人的疾患投入研发资金呢？
If businesses, like the pharmaceutical industry, are driven by the need to make a profit, how can we expect them to invest in R&D for diseases of the poor, who have no purchasing power?
应用推荐